|
1
|
Parkin DM, Bray F, Ferlay J and Pisani P:
Global cancer statistics, 2002. CA Cancer J Clin. 55:74–108. 2005.
View Article : Google Scholar
|
|
2
|
Miller WH Jr, Schipper HM, Lee JS, Singer
J and Waxman S: Mechanisms of action of arsenic trioxide. Cancer
Res. 62:3893–3903. 2002.PubMed/NCBI
|
|
3
|
Gensini GF, Conti AA and Lippi D: The
contributions of Paul Ehrlich to infectious disease. J Infect.
54:221–224. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Docampo R and Moreno SN: Current
chemotherapy of human African trypanosomiasis. Parasitol Res.
90(Supp 1): S10–S13. 2003.
|
|
5
|
Soignet SL, Maslak P, Wang ZG, et al:
Complete remission after treatment of acute promyelocytic leukemia
with arsenic trioxide. N Engl J Med. 339:1341–1348. 1998.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Shen ZX, Chen GQ, Ni JH, et al: Use of
arsenic trioxide (As2O3) in the treatment of
acute promyelocytic leukemia (APL): II. Clinical efficacy and
pharmacokinetics in relapsed patients. Blood. 89:3354–3360.
1997.PubMed/NCBI
|
|
7
|
Soignet SL, Frankel SR, Douer D, et al:
United States multicenter study of arsenic trioxide in relapsed
acute promyelocytic leukemia. J Clin Oncol. 19:3852–3860.
2001.PubMed/NCBI
|
|
8
|
Jiang XH, Wong BC, Yuen ST, et al: Arsenic
trioxide induces apoptosis in human gastric cancer cells through
up-regulation of p53 and activation of caspase-3. Int J Cancer.
91:173–179. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Seol JG, Park WH, Kim ES, et al: Effect of
arsenic trioxide on cell cycle arrest in head and neck cancer cell
line PCI-1. Biochem Biophys Res Commun. 265:400–404. 1999.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Akao Y, Nakagawa Y and Akiyama K: Arsenic
trioxide induces apoptosis in neuroblastoma cell lines through the
activation of caspase 3 in vitro. FEBS Lett. 455:59–62. 1999.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Shen ZY, Shen J, Li QS, Chen CY, Chen JY
and Yi Z: Morphological and functional changes of mitochondria in
apoptotic esophageal carcinoma cells induced by arsenic trioxide.
World J Gastroenterol. 8:31–35. 2002.PubMed/NCBI
|
|
12
|
Uslu R, Sanli UA, Sezgin C, et al: Arsenic
trioxide-mediated cytotoxicity and apoptosis in prostate and
ovarian carcinoma cell lines. Clin Cancer Res. 6:4957–4964.
2000.PubMed/NCBI
|
|
13
|
Hussein MA, Saleh M, Ravandi F, Mason J,
Rifkin RM and Ellison R: Phase 2 study of arsenic trioxide in
patients with relapsed or refractory multiple myeloma. Br J
Haematol. 125:470–476. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Kim KB, Bedikian AY, Camacho LH,
Papadopoulos NE and McCullough C: A phase II trial of arsenic
trioxide in patients with metastatic melanoma. Cancer.
104:1687–1692. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Lin CC, Hsu C, Hsu CH, Hsu WL, Cheng AL
and Yang CH: Arsenic trioxide in patients with hepatocellular
carcinoma: a phase II trial. Invest New Drugs. 25:77–84. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Schiller GJ, Slack J, Hainsworth JD, et
al: Phase II multicenter study of arsenic trioxide in patients with
myelodysplastic syndromes. J Clin Oncol. 24:2456–2464. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Whisler LC, Wood NB, Caldarelli DD, et al:
Regulators of proliferation and apoptosis in carcinoma of the
larynx. Laryngoscope. 108:630–638. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Evens AM, Tallman MS and Gartenhaus RB:
The potential of arsenic trioxide in the treatment of malignant
disease: past, present, and future. Leuk Res. 28:891–900. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Soignet SL: Clinical experience of arsenic
trioxide in relapsed acute promyelocytic leukemia. Oncologist.
6(Suppl 2): 11–16. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Chen GQ, Shi XG, Tang W, et al: Use of
arsenic trioxide (As2O3) in the treatment of
acute promyelocytic leukemia (APL): I. As2O3
exerts dose-dependent dual effects on APL cells. Blood.
89:3345–3353. 1997.PubMed/NCBI
|
|
21
|
Shao W, Fanelli M, Ferrara FF, et al:
Arsenic trioxide as an inducer of apoptosis and loss of PML/RAR
alpha protein in acute promyelocytic leukemia cells. J Natl Cancer
Inst. 90:124–133. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Seol JG, Park WH, Kim ES, et al: Potential
role of caspase-3 and -9 in arsenic trioxide-mediated apoptosis in
PCI-1 head and neck cancer cells. Int J Oncol. 18:249–255.
2001.PubMed/NCBI
|
|
23
|
Wang W, Qin SK, Chen BA and Chen HY:
Experimental study on antitumor effect of arsenic trioxide in
combination with cisplatin or doxorubicin on hepatocellular
carcinoma. World J Gastroenterol. 7:702–705. 2001.PubMed/NCBI
|
|
24
|
Li H, Zhu X, Zhang Y, Xiang J and Chen H:
Arsenic trioxide exerts synergistic effects with cisplatin on
non-small cell lung cancer cells via apoptosis induction. J Exp
Clin Cancer Res. 28:1102009. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Zhang N, Wu ZM, McGowan E, et al: Arsenic
trioxide and cisplatin synergism increase cytotoxicity in human
ovarian cancer cells: therapeutic potential for ovarian cancer.
Cancer Sci. 100:2459–2464. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Chung WH, Sung BH, Kim SS, Rhim H and Kuh
HJ: Synergistic interaction between tetra-arsenic oxide and
paclitaxel in human cancer cells in vitro. Int J Oncol.
34:1669–1679. 2009.PubMed/NCBI
|
